Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection.
Adult
Anti-HIV Agents
/ therapeutic use
Antigen-Antibody Complex
Antiretroviral Therapy, Highly Active
Biomarkers
/ blood
Chronic Disease
Cohort Studies
Enzyme-Linked Immunosorbent Assay
/ methods
Female
HIV Core Protein p24
/ blood
HIV Infections
/ blood
Humans
Hydrogen-Ion Concentration
Male
Sensitivity and Specificity
ELISA
Gag p24
HIV p24 antigen
HIV/AIDS
Simoa
biomarker
plasma
plasma marker
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
24 06 2021
24 06 2021
Historique:
pubmed:
7
5
2021
medline:
25
8
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
HIV-1 Gag p24 has long been identified as an informative biomarker of HIV replication, disease progression, and therapeutic efficacy, but the lower sensitivity of immunoassays in comparison to molecular tests and the interference with antibodies in chronic HIV infection limit its application for clinical monitoring. The development of ultrasensitive protein detection technologies may help in overcoming these limitations. Here, we evaluated whether immune complex dissociation combined with ultrasensitive digital enzyme-linked immunosorbent assay (ELISA) single-molecule array (Simoa) technology could be used to quantify p24 in plasma samples from people with HIV-1 infection. We found that, among different immune complex dissociation methods, only acid-mediated dissociation was compatible with ultrasensitive p24 quantification by digital ELISA, strongly enhancing p24 detection at different stages of HIV-1 infection. We show that ultrasensitive p24 levels correlated positively with plasma HIV RNA and HIV DNA and negatively with CD4-positive (CD4
Identifiants
pubmed: 33952636
pii: JVI.00016-21
doi: 10.1128/JVI.00016-21
pmc: PMC8223962
doi:
Substances chimiques
Anti-HIV Agents
0
Antigen-Antibody Complex
0
Biomarkers
0
HIV Core Protein p24
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0001621Références
Cytokine. 2016 May;81:109-16
pubmed: 26986868
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
Open Forum Infect Dis. 2020 Jan 11;7(2):ofz549
pubmed: 32083147
PLoS One. 2012;7(3):e24243
pubmed: 22448211
Nature. 2012 Jul 25;487(7408):439-40
pubmed: 22836995
J Clin Microbiol. 2002 Jul;40(7):2472-5
pubmed: 12089264
J Pathol. 2008 Jan;214(2):231-41
pubmed: 18161758
Nat Biotechnol. 2010 Jun;28(6):595-9
pubmed: 20495550
AIDS. 2018 Sep 24;32(15):2089-2102
pubmed: 30102659
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):557-62
pubmed: 16652029
J Virol Methods. 2013 Mar;188(1-2):153-60
pubmed: 23036750
Int J Antimicrob Agents. 2000 Dec;16(4):441-5
pubmed: 11118855
PLoS Med. 2008 Oct 21;5(10):e203
pubmed: 18942885
Cell Host Microbe. 2017 Apr 12;21(4):494-506.e4
pubmed: 28407485
PLoS One. 2011 Jan 18;6(1):e14544
pubmed: 21267446
J Infect Dis. 2021 Jun 4;223(11):1934-1942
pubmed: 33075121
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8783-8
pubmed: 27432972
AIDS Res Hum Retroviruses. 1993 Dec;9(12):1251-5
pubmed: 8142142
Pediatr Infect Dis J. 2000 Jun;19(6):544-51
pubmed: 10877171
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32554924
J Clin Microbiol. 2018 Jul 26;56(8):
pubmed: 29793968
J Infect Dis. 2002 Oct 15;186(8):1181-5
pubmed: 12355373
J Infect Dis. 2010 Jun 15;201(12):1796-805
pubmed: 20446847
N Engl J Med. 1993 Feb 4;328(5):297-302
pubmed: 8419814
AIDS. 1996 Sep;10(10):1085-90
pubmed: 8874624
Nat Commun. 2018 Aug 27;9(1):3450
pubmed: 30150664
J Virol. 2017 Feb 28;91(6):
pubmed: 28077644
J Clin Microbiol. 2005 Feb;43(2):857-61
pubmed: 15695692
Clin Chem. 2015 Nov;61(11):1372-80
pubmed: 26369787
J Virol Methods. 1993 Jul;43(2):247-56
pubmed: 8366170
AIDS Rev. 2002 Apr-Jun;4(2):83-92
pubmed: 12152521
J Virol Methods. 2003 Oct;113(1):29-34
pubmed: 14500124
J Infect Dis. 1995 Oct;172(4):1091-5
pubmed: 7561186
Clin Vaccine Immunol. 2016 Apr 04;23(4):249-53
pubmed: 26936099
J Immunol Methods. 1998 Aug 1;217(1-2):143-51
pubmed: 9776584
J Infect Dis. 2000 Apr;181(4):1280-8
pubmed: 10751136
J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):292-9
pubmed: 12843739
Science. 1996 May 24;272(5265):1167-70
pubmed: 8638160
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3704-3710
pubmed: 32029589
J Virol. 2015 Nov 11;90(2):1148-51
pubmed: 26559833
PLoS One. 2012;7(10):e46143
pubmed: 23056251
Lancet Infect Dis. 2014 Jun;14(6):459-67
pubmed: 24726095
AIDS. 2010 Mar 27;24(6):819-31
pubmed: 20224308
J Med Virol. 2009 Feb;81(2):217-23
pubmed: 19107966
Clin Infect Dis. 2016 Oct 1;63(7):984-990
pubmed: 27343547
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):345-9
pubmed: 18545150
Nat Commun. 2018 Dec 13;9(1):5305
pubmed: 30546110
J Lab Autom. 2016 Aug;21(4):533-47
pubmed: 26077162
J Int AIDS Soc. 2017 Jun 28;20(1):21579
pubmed: 28691435
Immunity. 2013 Oct 17;39(4):633-45
pubmed: 24138880
Clin Infect Dis. 2006 Mar 1;42(5):709-15
pubmed: 16447119
Clin Infect Dis. 2018 May 2;66(10):1519-1527
pubmed: 29211834
Int Arch Allergy Immunol. 2003 Nov;132(3):196-209
pubmed: 14646380
J Infect Dis. 2011 Jun 1;203(11):1637-46
pubmed: 21592994
AIDS. 1993 Oct;7(10):1331-6
pubmed: 8267905
J Acquir Immune Defic Syndr (1988). 1994 Jul;7(7):676-80
pubmed: 8207645